Skip to main content
Category

News

Building a Life Sciences Innovation District in Prince William County on BioTalk

By BioTalk with Rich Bendis Podcast, News

This episode of the BioTalk with Rich Bendis Podcast brings together leaders from industry, academia, and economic development to unpack the vision behind a new life sciences Innovation District anchored in Prince William County. With introductions to NAUGEN, George Mason University’s Institute for Biohealth Innovation, and the Prince William County Department of Economic Development, setting the stage for how each organization contributes to the district’s foundation. The guests discuss the life science assets, research strengths, and translational capabilities that define the district and explain why it is well-positioned to support biotechnology and advanced R&D companies.

The podcast explores how the partnership between Prince William County, George Mason University, and the City of Manassas came together, outlining the distinct roles each plays in advancing a shared strategy. The episode also introduces the NISA program, detailing how it supports companies seeking a soft-landing pathway into the district, the types of organizations best suited for the program, and the facilities, talent, and collaborative resources participants can access both immediately and over time.

Listen now via your favorite podcast platform:
Apple: https://apple.co/4p94Dqe
Spotify: https://bit.ly/3Y7dJZw
iHeart Podcasts: https://ihr.fm/3KLV7v4
Amazon Music Podcasts: https://amzn.to/4pajS1P
YouTube Music Podcasts: https://bit.ly/4phRV8I
TuneIn: https://bit.ly/44GoG7Y

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Jaehan Park is Founder and CEO of NAUGEN, a global innovation accelerator advancing novel technologies across life sciences and deep tech. With more than 25 years of experience in strategy and business development, he has led collaborations spanning cancer immunotherapy, vaccines, and biologics with global pharmaceutical companies and academic institutions. He leads the NISA Program in partnership with George Mason University and serves as a Mentor-in-Residence at KIC DC, supporting international startups entering U.S. markets.

Amy Adams is Executive Director of George Mason University’s Institute for Biohealth Innovation, where she advances biohealth research and innovation across more than 300 faculty and thousands of students. Her work focuses on partnerships, shared research infrastructure, and building hubs that connect academia with industry. She is co-leading the development of the Innovation District anchored at Mason’s SciTech campus and serves on the boards of BioHealth Innovation and the Association of University Research Parks.

Christina Winn leads the Prince William County Department of Economic Development, guiding investment, business growth, and redevelopment efforts across one of Virginia’s largest counties. She is overseeing the development of a research-driven Innovation District in partnership with George Mason University and the City of Manassas, supported by a GO Virginia grant. Her career includes leading large-scale economic development initiatives that have driven significant capital investment, job creation, and national visibility for the region.

BHI EIR Insights: 7 Tactics to Optimize Launch Messaging – Part II

By EIR Insights, News

by Jonathan Kay, MPP, Managing Partner, Health Market Experts & BioHealth Innovation, Inc. Entrepreneur-in-Residence

Last week, we introduced our series, Optimizing Launch Messaging. We began by encouraging testing communications rather than guessing about what will work best.

Testing provides data and evidence. Evidence matters in prevention, diagnosis, and treatment. Likewise, evidence matters when it comes to the performance of messaging and communications. It’s an important reminder for leaders in marketing, commercialization, medical affairs, communications, and others.

Tactic #2: Know Your Stakeholders to Avoid a One-Size-Fits-All Approach

In healthcare, a one-size-fits-all approach is a recipe for noise, not impact.

“Knowing” your stakeholders is much more than knowing their title, role, or level; it’s about understanding their role, baseline knowledge, priorities, motivations, and behavior. And what they value. All of that can vary. That’s why we segment the market and test messages by segment.

Not everyone needs the same message, even if they need similar information. The healthcare stakeholder landscape is complex and includes: physicians, NP/PAs, other providers; patients, caregivers, and patient advocacy groups; payer decision makers; policy influencers; health system executives; a variety of specialties and settings of care; and more!

To be effective💡, communication needs to be precise and purposeful.

Who is the message for? What information do they need? Will the message fulfill its purpose? Will the message influence opinions and motivate behavior? The goal is to deliver messages that are relevant, credible, and actionable.

Recently, I worked with a team supporting a start-up that has a new technology in cell therapy. The value proposition is relevant to stakeholders in therapy development, manufacturing, commercial / clinical use. In discussions with representatives from all of those functions, it became clear some features and functionality were valued by all stakeholders; the importance of other attributes varied by role or individual. We learned how to optimize telling the story of the technology for different audiences. The result? Precision messaging for precision medicine. 🎯

If your organization is preparing for launch, connect with us to learn more about how Health Market Experts can help you execute and maximize the success of your product launch with optimal positioning and messaging.

This post was written with NI not AI (written by a human using natural intelligence).

This post expands on content I previously wrote as a blog at Catalant and delivered in guest lectures at Rutgers Business School.

Visit https://www.linkedin.com/in/jonathan-kay-healthcare/ to connect with Jon on LinkedIn.

Unlocking Federal Funding with Jon Nelson, Director of Client Engagement at BioHealth Innovation, for Johns Hopkins Technology Ventures

By News

Jon Nelson, PhD

Securing non-dilutive funding is often a turning point for early-stage companies looking to scale while preserving ownership. Federal programs such as SBIR, STTR, and state-backed translational grants can provide critical capital, but the process is complex, competitive, and time-intensive without the right strategy.

In a recent presentation delivered to Johns Hopkins Technology Ventures, BioHealth Innovation’s Director of Client Engagement, Jon Nelson, shared a practical overview titled “Unlocking Federal Funding: SBIR, STTR, and Other Non-Dilutive Opportunities.” The session walks through how startups can assess eligibility, understand agency timelines, and build stronger submissions for programs supported by NIH, NSF, ARPA-H, and other federal partners. Rather than focusing on theory, the discussion centers on what reviewers look for and how teams can position both their technology and commercialization plan more effectively.

Jon brings a blend of academic and industry experience to this work. He holds a PhD in biology from Wake Forest University and has spent more than seven years supporting startups through the grant writing and commercialization process. At BioHealth Innovation, he works closely with founders on strategic grant development, pitch coaching, and aligning funding pathways with longer-term business goals.

The full presentation is available to watch and serves as a useful resource for founders, research teams, and innovation leaders exploring non-dilutive funding as part of their growth strategy.

Watch the full session here: https://vimeo.com/1146996020

Entrepreneurs in Residence Call: Biohealth Commercialization Leaders with AI and Quantum Experience

By News

BioHealth Innovation is expanding its Entrepreneurs in Residence (EIR) network and is seeking experienced leaders at the intersection of biohealth and advanced technologies, including artificial intelligence and quantum computing.

This call is for seasoned operators with a strong commercialization background. Ideal candidates have taken innovations from concept through market entry, licensing, spinout, or acquisition, and understand the realities of regulatory pathways, customer discovery, fundraising, and scale. Experience working with startups, academic technologies, government labs, or early-stage venture-backed companies is essential. EIRs serve in a part time advisory role with BHI, working flexibly alongside other professional commitments while contributing hands on commercialization expertise.

We are particularly interested in EIRs who can translate AI and quantum capabilities into practical biohealth applications, including drug discovery, diagnostics, clinical research, manufacturing, data analytics, and health system innovation. The role requires comfort working across technical, business, and stakeholder environments.

EIRs work closely with entrepreneurs, researchers, and partners across the BioHealth Capital Region and nationally. Engagements may include advising project teams, supporting partner initiatives, guiding commercialization strategy, and mentoring founders navigating early growth decisions.

This is an opportunity to contribute deep expertise to high-potential biohealth innovations while remaining connected to a collaborative, mission-driven ecosystem.

Interested candidates should contact BHI Founder, President, and CEO, Rich Bendis at rbendis@biohealthinnovation.org, with a summary of their background, commercialization experience, and areas of technical focus.

 

Building Quantum Momentum in the BioHealth Capital Region with IonQ’s Matthew Keesan on BioTalk

By BioTalk with Rich Bendis Podcast, News

IonQ Vice President and GM of Quantum Platform Matthew Keesan joins BioTalk for a clear look at how they are advancing quantum computing from its home base in the BioHealth Capital Region. He shares the story of IonQ’s Maryland roots and explains quantum computing in straightforward terms for listeners seeking a high-level understanding. The conversation moves into why biohealth leaders should track the hardware race, what distinguishes IonQ’s approach, and how quantum is already being paired with AI to strengthen modeling and analysis. Keesan walks through early use cases showing traction today, challenges common myths about timelines, and shares which biohealth applications he expects to gain mainstream momentum by 2030.

Listen via your favorite Podcast Platform:
Apple: https://apple.co/4qfo8ON
Spotify: https://bit.ly/3KXjINr
iHeart Podcasts: https://ihr.fm/4q3DaH8
Amazon Music Podcasts: https://amzn.to/3MBCaM2
YouTube Music Podcasts: https://bit.ly/4qab0uf 
TuneIn: https://bit.ly/3MECNEA

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Matthew Keesan is Vice President and GM of Quantum Platform at IonQ and a member of the BHI Board. He joined IonQ in 2017 to lead the development of the company’s Quantum OS, the software stack that controls IonQ’s quantum computers. In 2021, he oversaw the launch of IonQ’s Harmony systems on Amazon Braket, Microsoft Azure Quantum, and Google Cloud, making IonQ the first quantum hardware provider available across all three hyperscalers. He built IonQ’s security function to meet commercial and government frameworks, including SOC 2, NIST 800-171, NIST 800-53, and ISO 27001, and established a globally distributed operations team managing IonQ’s fleet of quantum computers across the United States and Europe.

Before joining IonQ, Keesan served as CTO of the restaurant technology company Ando, which was acquired by Uber, and advised startups in manufacturing, e-commerce, and identity-as-a-service. He also helped create the technology behind the interactive HBO series Mosaic with Steven Soderbergh. He holds patents in quantum compilation, hybrid quantum computation, and quantum control automation, and has co-authored papers published in Nature and Physical Review A.

BHI EIR Insights: 7 Tactics to Optimize Launch Messaging – Part I

By EIR Insights, News

by Jonathan Kay, MPP, Managing Partner, Health Market Experts & BioHealth Innovation, Inc. Entrepreneur-in-Residence

Healthcare is complicated. Communicating effectively doesn’t need to be.

For a new medical technology, biologic, pharmaceutical, or digital health solution, a critical element of go-to-market strategy (GTM) and initial commercial success is messaging.

But messaging often doesn’t get the attention it deserves.

GTM messaging could include messages to any: physicians, hospital administrators, policy makers, patients, caregivers, payers, and more.

This post kicks off our 7-part series on Optimizing Launch Messaging 🚀, where we will share 7 valuable tactics to help achieve your goals related to access, commercial success, and improved patient outcomes.

Tactic 1: Test, Don’t Guess

The first step to optimizing launch strategy is embracing a data-driven mindset:

Healthcare markets are complex in so many ways. Think of the scientific, clinical, regulatory, reimbursement, and competitive landscape. Testing in a complex and changing environment helps minimize risk and maximize potential.

Companies run clinical trials to test the impact of a therapy. Similarly, commercial teams should test their launch communications to ensure they are effective and safe. That is, are the messages clear, credible, and persuasive? Do the messages avoid unintended consequences?

Why test messages? We test messages to:

  • Understand unmet needs
  • Assess competitive differentiators
  • Understand which messages resonate and why
  • Learn how to motivate appropriate behavior

Do you have a positive example from when you tested messages in advance of using them? Share your thoughts below!

At Health Market Experts, we make corporate and brand messaging more efficient and effective. If your organization is preparing to launch a product or a campaign, connect with us to learn more about how we can help you develop and execute your launch plan and maximize success. Ask us about message awareness and attribution, too.

This post was written with NI not AI (written by a human using natural intelligence).

This post expands on content I previously wrote as a blog at Catalant and delivered in guest lectures at Rutgers Business School.

Visit https://www.linkedin.com/in/jonathan-kay-healthcare/ to connect with Jon on LinkedIn.

Quantum, Biohealth, and the Future of Innovation with Strangeworks Founder and CEO Whurley on BioTalk

By BioTalk with Rich Bendis Podcast, News

William Hurley, known widely as Whurley, joins BioTalk for a deep look at how quantum computing is moving from theory into practical use across the biohealth landscape. He opens the conversation with an introduction to Strangeworks and explains why the company is focused on making quantum computing more accessible for real-world problem-solving. The discussion explores how quantum could support breakthroughs in genomics and personalized medicine, improve the way clinical trials are modeled, and strengthen manufacturing and supply chain operations. Whurley also talks through the ingredients required for regional leadership in this space, including infrastructure, strategic partnerships, and a specialized workforce. He shares his view on what will distinguish successful players in quantum from those who overpromise or misread the market, and closes with a forward look at the convergence of quantum, AI, and biotechnology and the impact these capabilities could have on healthcare innovation. The conversation follows his recent keynote appearance at the BioHealth Capital Region Forum this past September.

Listen on your favorite podcasting platforms:
Apple: https://apple.co/4ppTmml
Spotify: https://bit.ly/48pIjDt
iHeart Podcasts: https://ihr.fm/4oKdMFx
Amazon Music Podcasts: https://amzn.to/3MgH694
YouTube Music Podcasts: https://bit.ly/4pqw53G
TuneIn: https://bit.ly/4a4lJl4

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Whurley is the founder and CEO of Strangeworks, an Eisenhower Fellow, a Senior Member of the IEEE, founder of the Quantum Computing Standards Workgroup at the IEEE, the first Ambassador to CERN and Society, and co-author of “Quantum Computing for Babies” and the forthcoming “Quantum Computing for Dummies.” He previously served as a Managing Director at Goldman Sachs following its acquisition of his startup Honest Dollar. Before that he founded Chaotic Moon Studios, which was acquired by Accenture.

Strengthening Virginia’s BioHealth Future with Secretary of Commerce and Trade Juan Pablo Segura on BioTalk

By BioTalk with Rich Bendis Podcast, News

Secretary Juan Pablo Segura joins BioTalk for a conversation about Virginia’s growing position in the biohealth economy and the statewide strategy behind it. He outlines the significance of the new partnership with AstraZeneca, Lilly, and Merck, including up to $120 million in private investment to create a workforce development center and expand the Commonwealth’s life sciences capacity. Segura talks through how Virginia approaches company recruitment, what investors are responding to, and why the state is seeing increased interest from biomanufacturing and advanced R&D companies. He also discusses Virginia’s use of public-private partnerships to accelerate industry growth, strengthen the talent pipeline, and support emerging hubs across the Commonwealth. The conversation closes with a look at Virginia’s role in the BioHealth Capital Region and how the regional identity helps amplify the state’s message as it continues building a competitive biohealth ecosystem.

Listen now on your favorite podcast platform:
Apple: https://apple.co/3M2UNbB
Spotify: https://bit.ly/4izRPYa
iHeart Podcasts: https://ihr.fm/3Ktc0u5
Amazon Podcasts: https://amzn.to/3K5kkjN
YouTube Music Podcasts: https://bit.ly/4owIZfc
TuneIn: https://bit.ly/4ptw26O


Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Juan Pablo Segura is the Secretary of Commerce and Trade for the Commonwealth of Virginia. He leads 13 agencies focused on economic growth, business development, and industry expansion across the state. Before entering public service, Segura spent his career building companies in the digital health sector, most notably as a founder of Babyscripts, a widely adopted maternity care platform. His work has been recognized by Startup Health, CTIA, EY, and the White House. He is a CPA and a graduate of the University of Notre Dame, and he lives in Henrico, Virginia with his family.

Activation Capital Names Michael Steele as President and CEO

By News

Accomplished life sciences executive to lead Virginia’s innovation ecosystem development organization into its next phase of growth.

Richmond, VA – August 26, 2025 – The Virginia Biotechnology Research Partnership Authority (doing business as Activation Capital) announced today that it has appointed Michael Steele as president and chief executive officer. Steele succeeds Robert Ward, who has served as interim CEO since July 2024 during a period of rapid growth for the life sciences ecosystem development organization.

Steele comes to Activation Capital with more than two decades of leadership experience in therapeutic, diagnostic, and research verticals across global markets. He has built and led high-performing teams, driven corporate strategy, and delivered growth through business development, mergers and acquisitions, licensing, investor relations, and strategic partnerships. Over his career, he has held senior leadership positions at fast-paced organizations, including Biocartis, Chembio Diagnostics, SeraCare Life Sciences, and Serologicals. Steele served in general management, corporate development, commercial, and operational roles, where he executed transactions generating hundreds of millions of dollars in revenue and investment. He has led global partnering initiatives to advance therapeutic, diagnostic and precision medicine innovations, negotiated agreements with top biopharma and life science companies, and directed strategies for large, growing organizations.

A Virginia native, Steele earned his MBA and a Bachelor of Science degree from James Madison University and completed the Senior Leadership Program at Vlerick Business School in Brussels, Belgium.

“Activation Capital’s mission depends on exceptional leadership, and Michael brings the vision, expertise and collaborative spirit needed to position the organization for even greater impact. We are excited to bring him on board,” said Michael Rao, president of Virginia Commonwealth University and chair of the Activation Capital Board. “I also thank Robert Ward for his dedicated service as interim CEO. Rob brought amazing energy, experience and leadership into his role; he streamlined infrastructure and processes, helped to achieve financial clarity and used his real estate expertise to guide the Board in understanding complex transactions.”

“Activation Capital’s continued success in advancing Virginia’s life sciences ecosystem depends on its ability to translate bold innovation into long-term, sustainable economic growth,” said Juan Pablo Segura, Secretary of Commerce and Trade for the Commonwealth of Virginia. “Under Michael Steele’s leadership, Activation Capital is well positioned to catalyze new partnerships, attract investment, and expand our regional impact further. I look forward to working together to ensure Virginia remains at the forefront of biotech innovation.”

“Michael brings deep experience in life sciences, business development, and strategic vision that will be a tremendous asset to Activation Capital and to Virginia’s innovation economy as a whole,” said Garrison Coward, board member of the Virginia Biotechnology Research Partnership Authority and Deputy Chief Transformation Officer in the Office of the Governor. “He clearly knows how to build partnerships, drive growth, and move organizations forward. That combination will help strengthen our position in biotech innovation across Central Virginia and the Commonwealth.”

Steele joins Activation Capital during a period of expansion and national recognition. Over the past year, the organization launched the Frontier BioHealth accelerator and showcase, welcomed its inaugural cohort of 10 high-growth startups, created Pioneer Connect, and expanded Start-the-Journey, a pre-accelerator for emerging founders. Activation Capital also secured a multimillion-dollar GO Virginia grant to scale biohealth sector development and earned recognition for its role in building an inclusive, high-impact innovation economy.

“I am energized and honored to lead Activation Capital at this pivotal moment,” said Michael Steele. “We’re building on a strong foundation, growing our programs, supporting even more entrepreneurs, and expanding our impact across the Commonwealth. In our mission of elevating Virginia’s life science ecosystem, my goal is simple yet impactful: create meaningful jobs and attract investments to catalyze our researchers, entrepreneurs, and partners to bring innovation to life, right here in the Commonwealth.”

About Virginia Biotechnology Research Partnership Authority

The Virginia Biotechnology Research Partnership Authority (“Authority”) is a political subdivision of the Commonwealth of Virginia created by Chapter 946 of the 1993 Virginia Acts of Assembly (the “Act”). The Authority disseminates knowledge pertaining to scientific and technological research and development among public and private entities, including but not limited to knowledge in biotechnology, and promotes industrial and economic development.

For more information, visit activation.capital.

MEDIA CONTACTS:

Leslie Strickler
leslies@etrecommunications.com

Paul Spicer
pauls@etrecommunications.com

Investigational Rosnilimab Emerges as a Novel, Differentiated Treatment Option for Rheumatoid Arthritis

By News
Investigational Rosnilimab Emerges as a Novel, Differentiated Treatment Option for Rheumatoid Arthritis

Rosnilimab, a selective depleter of pathogenic T cells, is a potential game changer for the treatment of moderate-to-severe rheumatoid arthritis (RA).

In a new Phase 2b clinical trial, rosnilimab demonstrated rapid symptomatic improvement driving patients into low disease activity (LDA) across diverse patient populations, including difficult-to-treat patients, by three months that continued to improve through six months. The data further indicated these responses were durable for at least three additional months off-drug. Rosnilimab also demonstrated favorable safety and tolerability, particularly when compared to the safety profiles of standard of care biologics or JAK inhibitors.1

“Witnessing rosnilimab, with its novel mode of action, dramatically reduce RA disease activity through six months in most patients, whether having failed biologic or targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) therapies or b/tsDMARD-naïve, is truly exciting for patients living with this disease and the field of RA treatment,” said Jonathan Graf, M.D., professor of Medicine, Division of Rheumatology at the University of California, San Francisco, and a lead investigator for the trial.

The U.S. RA market is valued at more than $20 billion. Even after patients have progressed on first-line biologics (anti-TNFs), the second line+ RA market generates more than $10 billion in annual revenue. For instance, rituximab, a B cell depleter with a significant adverse event profile including an increased risk of infection, prior to going off patent in 2018 and the entrance of biosimilars, achieved nearly $2 billion in annual RA sales. And today, despite biosimilar competition, it still maintains a significant share of last-line therapy sales in RA. Since 2012, no new treatment classes have been approved, and many RA patients cycle through different treatment therapies2, with up to a quarter not finding symptom relief.3

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.